Michael acceptor containing drugs are a novel class of 5-lipoxygenase inhibitor targeting the surface cysteines C416 and C418

Fixed Oil of<i>Nigella sativa</i>and Derived Thymoquinone Inhibit Eicosanoid Generation in Leukocytes and Membrane Lipid Peroxidation

Peter J. Houghton, Rema Zarka, Beatriz de las Heras et al. · Planta Medica · 1995 · 786 citations

Life Sciences, Biochemistry, Pharmacology +14

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Arlene Chan, Suzette Delaloge, Frankie A. Holmes et al. · The Lancet Oncology · 2016 · 565 citations

Medicine, Oncology, Breast Oncology +13

Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles

Iana M. Serafimova, Miles A. Pufall, Shyam Krishnan et al. · Nature Chemical Biology · 2012 · 500 citations

Natural Sciences, Biochemistry, Chemistry +12

The Structure of Human 5-Lipoxygenase

Nathaniel C. Gilbert, Sue G. Bartlett, Maria T. Waight et al. · Science · 2011 · 422 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +10

Plumbagin (5-Hydroxy-2-methyl-1,4-naphthoquinone) Suppresses NF-κB Activation and NF-κB-regulated Gene Products Through Modulation of p65 and IκBα Kinase Activation, Leading to Potentiation of Apoptosis Induced by Cytokine and Chemotherapeutic Agents

Santosh K. Sandur, Haruyo Ichikawa, Gautam Sethi et al. · Journal of Biological Chemistry · 2006 · 320 citations · Full text

Medicine, Oncology, Pharmacology +17